We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Molecular Biological Assay Applied to Cancer Diagnostics

By LabMedica International staff writers
Posted on 21 Sep 2011
Minute particles that measure micro ribonucleic acid (miRNA) levels have been utilized in tissue samples to provide a method to scan and diagnose cancer. More...


The technology uses an array of particles that attach themselves to a specific type of miRNA and when exposed to tissue, blood samples or purified RNA, these particles enable a miRNA profile to be created.

Chemical engineers at Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) successfully used hydrogel particles, with a length of around 200 μm, to detect more easily and efficiently miRNA dysregulation patterns in samples taken from four individuals with cancer. Hydrogels are a type of polymer chain network that attract water causing the attachment of nucleic acids. The hydrogel particles are ornamented with millions of identical strands of DNA. The strands are complimentary to a specific miRNA target sequence. Consequently, miRNA in a blood sample will be attracted to and attach to the DNA on the hydrogel particle.

By mixing the hydrogel particles with a blood sample, any miRNA present binds to its respective DNA. The DNA strands on the hydrogel contain a short sequence that then binds to a fluorescent probe at the completion of the test. A custom designed microfluidic scanner is used to measure rapidly each particle's fluorescence, thus revealing how much miRNA is present. The scanner also reads a chemical barcode imprinted on each hydrogel particle, which identifies the type of miRNA being detected. The entire process is complete in less than three hours. By adding multiple DNA label sequences to each miRNA target, increases the sensitivity of the hydrogel miRNA-detection particles by as much as 100 times. This new approach is more accurate because different miRNA strands have different shapes, which affect how easily they bind to the DNA markers and using mixed DNA markers helps avoid this anomaly.

Patrick S. Doyle PhD, the lead author and a professor at MIT, and colleagues are now beginning work with medical researchers to study the use of miRNA detection for use in other diseases such as heart disease and HIV. Firefly Bioworks (Cambridge, MA, USA) will license the technology for the custom-made scanner that is needed to detect the fluorescence of the hydrogels, with an aim of providing a unit for commercial use. The study was published on August 3, 2011, in the journal Analytical Chemistry.

Related Links:
Massachusetts Institute of Technology
Firefly Bioworks



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.